In 2012, the US Preventive Services Task Force released a recommendation against routine use of prostate specific antigen (PSA) to screen for PCa (level of evidence [LoE]: D) because of growing concerns about overdiagnosis and overtreatment.3, 4. The gene discussed is KLK3; the disease is posterior cortical atrophy.